Keywords: map, leaps, up, 900m, deal, az, anglo-swedish
MAP leaps on up to $900M deal with AZ
Article | 12 January 2009
Anglo-Swedish drug major AstraZeneca has entered an exclusive worldwide agreement to develop and commercialize Unit Dose Budesonide, US firm MAP ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
